Select your country
Select a country to go to the website of the respective STADA sales company.
Czech Republic (2)
Saudi Arabia (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
STADA approves growth targets for 2019
- Press Release
- Investor News
Bad Vilbel, July 11, 2016, 1.17 p.m. –
The Executive Board of STADA Arzneimittel AG at its meeting today, on July 11, 2016, approved the medium-term growth targets for the Group.
A Group wide program to improve performance initiated by the Executive Board will also make a contribution toward the achievement of the growth targets. As part of the program, untapped sales potential will be leveraged, marketing expenses will be optimized and sales efficiency will be enhanced. In addition, plans call for reductions primarily in cost of sales and general and administrative expenses. Implementation of the program is expected to be completed in 2019.
The program is aimed primarily at increasing STADA’s competitiveness and improving innovative strength for sustainable value creation on behalf of shareholders.
The STADA growth forecast is based in particular on the following assumptions:
- primarily organic sales growth in the core segments of Generics and Branded Products
- no significant disposals with an effect on sales and earnings
- forward projection of current currency relations, the current interest rate levels and largely unchanged tax framework conditions in the countries where STADA has Group companies
- forward projection of current regulatory conditions in the markets relevant for STADA
- range of the forecast plus/minus 5%
For financial year 2016, the STADA Executive Board maintains its outlook, according to which slight growth in Group sales adjusted for currency and portfolio effects, adjusted EBITDA and adjusted net income is expected.
Chart STADA growth targets 2019
STADA key figure
Financial year 2015
Group sales adjusted for currency and portfolio effects
Euro 2.6 billion
Euro 2.11 billion
Euro 510 million
Euro 389.4 million
Adjusted net income
Euro 250 million
Euro 165.8 million
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: firstname.lastname@example.org
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: email@example.com
Or visit us in the Internet at www.stada.com.